PMC:7212949 / 16327-17007 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T78","span":{"begin":85,"end":93},"obj":"Body_part"},{"id":"T79","span":{"begin":117,"end":121},"obj":"Body_part"},{"id":"T80","span":{"begin":279,"end":284},"obj":"Body_part"}],"attributes":[{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T53","span":{"begin":117,"end":121},"obj":"Body_part"}],"attributes":[{"id":"A53","pred":"uberon_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T103","span":{"begin":63,"end":71},"obj":"Disease"},{"id":"T104","span":{"begin":103,"end":109},"obj":"Disease"},{"id":"T105","span":{"begin":232,"end":240},"obj":"Disease"},{"id":"T106","span":{"begin":469,"end":477},"obj":"Disease"}],"attributes":[{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T124","span":{"begin":117,"end":121},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T125","span":{"begin":117,"end":121},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T126","span":{"begin":159,"end":167},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T127","span":{"begin":224,"end":226},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T128","span":{"begin":279,"end":284},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T129","span":{"begin":335,"end":336},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T23","span":{"begin":505,"end":520},"obj":"Chemical"},{"id":"T24","span":{"begin":522,"end":524},"obj":"Chemical"},{"id":"T26","span":{"begin":527,"end":538},"obj":"Chemical"},{"id":"T27","span":{"begin":553,"end":563},"obj":"Chemical"},{"id":"T28","span":{"begin":565,"end":575},"obj":"Chemical"},{"id":"T29","span":{"begin":580,"end":591},"obj":"Chemical"},{"id":"T30","span":{"begin":599,"end":617},"obj":"Chemical"}],"attributes":[{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_24261"},{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A25","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T11","span":{"begin":546,"end":563},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-sentences","denotations":[{"id":"T200","span":{"begin":0,"end":482},"obj":"Sentence"},{"id":"T201","span":{"begin":483,"end":680},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T686","span":{"begin":160,"end":165},"obj":"UBERON:0002107"},{"id":"T687","span":{"begin":167,"end":175},"obj":"UBERON:0001264"},{"id":"T688","span":{"begin":200,"end":206},"obj":"UBERON:0002106"},{"id":"T689","span":{"begin":210,"end":219},"obj":"GO:0006915"},{"id":"T690","span":{"begin":248,"end":255},"obj":"GO:0007067"},{"id":"T691","span":{"begin":275,"end":286},"obj":"CL:0000182"},{"id":"T692","span":{"begin":307,"end":314},"obj":"UBERON:0009912"},{"id":"T693","span":{"begin":315,"end":326},"obj":"CL:0000542"},{"id":"T694","span":{"begin":350,"end":355},"obj":"GO:0005634"},{"id":"T695","span":{"begin":388,"end":393},"obj":"UBERON:0002107"},{"id":"T696","span":{"begin":428,"end":438},"obj":"UBERON:0001959"},{"id":"T697","span":{"begin":510,"end":513},"obj":"PR:000001004"},{"id":"T698","span":{"begin":533,"end":537},"obj":"PR:000002064"},{"id":"T699","span":{"begin":539,"end":551},"obj":"CL:0000235"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"LitCovid-PubTator","denotations":[{"id":"392","span":{"begin":251,"end":255},"obj":"Gene"},{"id":"393","span":{"begin":522,"end":526},"obj":"Gene"},{"id":"394","span":{"begin":580,"end":591},"obj":"Chemical"},{"id":"395","span":{"begin":599,"end":617},"obj":"Chemical"},{"id":"396","span":{"begin":63,"end":71},"obj":"Disease"},{"id":"397","span":{"begin":103,"end":121},"obj":"Disease"},{"id":"398","span":{"begin":232,"end":240},"obj":"Disease"},{"id":"399","span":{"begin":469,"end":477},"obj":"Disease"}],"attributes":[{"id":"A392","pred":"tao:has_database_id","subj":"392","obj":"Gene:59272"},{"id":"A393","pred":"tao:has_database_id","subj":"393","obj":"Gene:3569"},{"id":"A394","pred":"tao:has_database_id","subj":"394","obj":"MESH:D002738"},{"id":"A395","pred":"tao:has_database_id","subj":"395","obj":"MESH:D006886"},{"id":"A396","pred":"tao:has_database_id","subj":"396","obj":"MESH:C000657245"},{"id":"A397","pred":"tao:has_database_id","subj":"397","obj":"MESH:D055370"},{"id":"A398","pred":"tao:has_database_id","subj":"398","obj":"MESH:C000657245"},{"id":"A399","pred":"tao:has_database_id","subj":"399","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}

{"project":"2_test","denotations":[{"id":"32620220-32632819-2074061","span":{"begin":229,"end":231},"obj":"32632819"},{"id":"32620220-32167153-2074062","span":{"begin":364,"end":366},"obj":"32167153"},{"id":"32620220-32215613-2074063","span":{"begin":368,"end":370},"obj":"32215613"},{"id":"32620220-32155444-2074064","span":{"begin":376,"end":378},"obj":"32155444"}],"text":"Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.27 , 28 COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.29, 30, 31, 32 There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.33"}